echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > EJHF: Effects of sacubitril/valsartan versus valsartan on renal function in patients with heart failure with or without diabetes and preserved ejection fraction

    EJHF: Effects of sacubitril/valsartan versus valsartan on renal function in patients with heart failure with or without diabetes and preserved ejection fraction

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE: Diabetes mellitus is associated with a faster decline in renal function in patients with heart failure (HF)
    .


    Sacubitril/valsartan attenuated worsening of renal function with reduced ejection fraction in patients with diabetes and heart failure to a greater extent than renin-angiotensin system inhibitors alone


    Diabetes is associated with a faster decline in kidney function in patients with heart failure (HF)


    interaction _

    Figure 1.
    Effects of sacubitril/valsartan (SAC/Val) on time-dependent changes in glomerular filtration rate (EGFR) and composite renal outcomes in diabetic and non-diabetic patients
    .


    Adjusted means for EGFR over 192 weeks were obtained from a repeated-measures mixed-effects model


    Figure 1.


    Table 1 Estimated rate of glomerular filtration rate decline from baseline (ml/min/1.
    73m2/year)

    Table 1 Estimated rate of glomerular filtration rate decline from baseline (ml/min/1.
    73m2/year)

    Figure 2 Changes in estimated glomerular filtration rate (EGFR) over time in diabetic and nondiabetic patients
    .


    Adjusted means for EGFR over 192 weeks were obtained from a repeated-measures mixed-effects model


    Figure 2 Changes in estimated glomerular filtration rate (EGFR) over time in diabetic and nondiabetic patients


    Figure 3 Kaplan-Meier analysis of the effect of diabetes status on comprehensive renal prognosis
    .


    Probability of first occurrence of composite renal outcome (estimated glomerular filtration rate reduction from baseline by 50%, development of end-stage renal disease, or death attributable to renal causes) obtained from Kaplan-Meier failure analysis ≥50% reduction in estimated glomerular filtration rate from baseline, development of end-stage renal disease, or death attributable to renal causes)


    Figure 3 Kaplan-Meier analysis of the effect of diabetes status on comprehensive renal prognosis


    Table 3.
    Composite renal outcomes and their individual components

    Table 3.
    Composite renal outcomes and their individual components

    Figure 4 Combined renal outcomes (estimated 50% reduction in glomerular filtration rate from baseline, development of end-stage renal disease or death attributable to renal causes)
    .


    Estimated rate ratios and 95% confidence intervals were obtained using a negative binomial regression model for HbA1c with restricted cubic splines


    Figure 4 Combined renal outcomes (estimated 50% reduction in glomerular filtration rate from baseline, development of end-stage renal disease or death attributable to renal causes)


    Figure 4 Effect of T treatment with sacubitril/valsartan versus valsartan on the composite renal outcome (estimated glomerular filtration rate reduction [eGFR] ≥50% relative to baseline, end-stage renal disease development, or death from renal causes)
    .


    Estimated ratios and 95% confidence intervals were obtained from negative binomial regression models, and baseline eGFR was expressed by restricted cubic splines
    .

    Figure 4 Effect of T treatment with sacubitril/valsartan versus valsartan on the composite renal outcome (estimated glomerular filtration rate reduction [eGFR] ≥50% relative to baseline, end-stage renal disease development, or death from renal causes)
    .
    Estimated ratios and 95% confidence intervals were obtained from negative binomial regression models, and baseline eGFR was expressed by restricted cubic splines
    .

    Conclusions: Compared with valsartan, sacubitril/valsartan attenuated the decline in eGFR and reduced clinically relevant renal events in HFpEF patients with and without diabetes
    .

    Compared with valsartan, sacubitril/valsartan attenuated the decline in eGFR and reduced clinically relevant renal events in HFpEF patients with and without diabetes
    .

    Original source: Peikert A, Vaduganathan M, McCausland F, et al.
    Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF .
    Eur J Heart Fail 2022 Feb 04

    Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON- HF
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.